Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G7MM
|
|||
| Former ID |
DIB008294
|
|||
| Drug Name |
TA-8995
|
|||
| Synonyms |
Obicetrapib; UNII-8O74K609HN; 8O74K609HN; 866399-87-3; Obicetrapib [INN]; CHEMBL3785197; SCHEMBL17002081; AMG-899; DEZ-001; Obicetrapib (AMG-899 TA-8995); AKOS032954130; HY-18778; 4-((2-(((3,5-Bis(trifluoromethyl)phenyl)methyl)((2R,4S)-1- (ethoxycarbonyl)-2-ethyl-6-(trifluoromethyl)-1,2,3,4- tetrahydroquinolin-4-yl)amino)pyrimidin-5-yl)oxy)butanoic acid; 1(2H)-Quinolinecarboxylic acid, 4-(((3,5-bis(trifluoromethyl)phenyl)methyl)(5-(3-carboxypropoxy)-2-pyrimidinyl)amino)-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-,
Click to Show/Hide
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99, E78; ICD-9: 390-459] | Phase 2 | [1] | |
| Hyperlipidaemia [ICD-11: 5C80; ICD-10: E78.5] | Phase 2 | [2] | ||
| Company |
Mitsubishi Tanabe Pharma Corp
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C32H31F9N4O5
|
|||
| Canonical SMILES |
CCC1CC(C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=NC=C(C=N4)OCCCC(=O)O
|
|||
| InChI |
1S/C32H31F9N4O5/c1-3-22-14-26(24-13-19(30(33,34)35)7-8-25(24)45(22)29(48)49-4-2)44(28-42-15-23(16-43-28)50-9-5-6-27(46)47)17-18-10-20(31(36,37)38)12-21(11-18)32(39,40)41/h7-8,10-13,15-16,22,26H,3-6,9,14,17H2,1-2H3,(H,46,47)/t22-,26+/m1/s1
|
|||
| InChIKey |
NRWORBQAOQVYBJ-GJZUVCINSA-N
|
|||
| CAS Number |
CAS 866399-87-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cholesteryl ester transfer protein (CETP) | Target Info | Inhibitor | [3] |
| Panther Pathway | CCKR signaling map ST | |||
| Reactome | LDL-mediated lipid transport | |||
| HDL-mediated lipid transport | ||||
| WikiPathways | Statin Pathway | |||
| Lipid digestion, mobilization, and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT01970215) TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP). U.S. National Institutes of Health. | |||
| REF 3 | Amgen To Acquire Privately-Held Dezima Pharma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.